ClinicalTrials.gg
Not yet recruitingNCT07631910Updated Jun 8, 2026

Application of Multimodal Intervention in the Prevention of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgery

An interventional study of Amisulpride Injection and Dexamethasone (intravenous) in Nausea and Vomiting, Postoperative, sponsored by Sir Run Run Shaw Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Sir Run Run Shaw Hospital · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing amisulpride in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Amisulpride · Postoperative Nausea and Vomiting.

Planned enrollment
10th of 11
212 · median 453
Started
2026
with 1 other
No phase
2 of 11
2 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
Sir Run Run Shaw Hospital

Among the 11 studies testing amisulpride in Postoperative Nausea and Vomiting, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 2 with no phase, and was the 10th registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

2 of the 11 studies testing amisulpride in Postoperative Nausea and Vomiting are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About amisulpride

Amisulpride: first FDA approval 2020 (BARHEMSYS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Postoperative Nausea and Vomiting studies recruiting now, 22 (33%) set no upper age limit and 38 (58%) stop at 75 or younger; 15 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing amisulpride in Postoperative Nausea and Vomiting, or all of them as a file.
02

Study summary

  1. Background Postoperative nausea and vomiting (PONV) is a common complication after general anesthesia, with an incidence as high as 80% in gynecological laparoscopic surgery. Transcutaneous electrical acupoint stimulation (TEAS) has shown potential as a non-invasive, side-effect-free intervention. Combining pharmacological agents (dexamethasone or amisulpride) with TEAS may provide a synergistic preventive effect, aligning with enhanced recovery after surgery (ERAS) principles.
  2. Study Objectives To evaluate the preventive effect of TEAS on PONV in patients undergoing gynecological laparoscopic surgery, compared with sham stimulation.

    To explore the synergistic effect of dexamethasone or amisulpride when combined with TEAS, and to optimize PONV prevention strategies.

    To assess the impact of multimodal intervention on postoperative recovery quality, length of hospital stay, and patient satisfaction.

    To evaluate the safety of the combined interventions and record any adverse events.

  3. Study Design Design type: 2×2 factorial, randomized, double-blind (participants, outcome assessors, and data analysts blinded to group assignment).

    Randomization: 1:1:1:1 allocation using an online randomization tool.

    3.1 Study Groups Group Intervention A TEAS + Dexamethasone B TEAS + Amisulpride C Sham stimulation + Dexamethasone D Sham stimulation + Amisulpride 3.2 Participants Inclusion criteria: Age 18-65 years; ASA physical status I-II; scheduled for elective gynecological laparoscopic surgery (e.g., ovarian cystectomy, myomectomy) under general anesthesia; willing to provide informed consent.

    Exclusion criteria: Severe cardiac, hepatic, renal, or pulmonary disease; allergy or skin disease at TEAS application site; Receipt of antiemetics within 24 h before surgery; Implanted cardiac pacemaker, cardioverter-;pregnancy or lactation; vulnerable populations (e.g., critically ill, psychiatric disorders, cognitive impairment, illiteracy); any condition deemed unsuitable by the investigator.

    3.3 Interventions A wearable transcutaneous electrical acupoint stimulation (TEAS) wristband will be applied to the P6 (Neiguan) acupoint on the dominant upper extremity. The P6 acupoint is located approximately 3-5 cm proximal to the distal wrist crease, between the tendons of the flexor carpi radialis and palmaris longus. The device integrates the stimulating electrodes within the wristband and does not require external adhesive electrodes.

    TEAS or sham stimulation will be administered at three time points: 30 minutes before surgery and 24 and 48 hours after surgery, with each session lasting 30 minutes.

    Dexamethasone 5 mg (off-label for PONV; approved for inflammatory/allergic conditions).

    Amisulpride 5 mg.

    3.4 Outcome Measures

    Primary outcomes (0-48 h postoperatively):

    PONV incidence (proportion of patients with nausea, vomiting, or retching). PONV severity (0 = none, 1 = nausea only, 2 = vomiting/retching, 3 = refractory nausea/vomiting).

    Secondary outcomes:

    Recovery quality: time to first flatus, first ambulation, hospital stay, bowel function recovery.

    Patient satisfaction: Visual Analogue Scale (VAS, 0-10) and QoR-15 score (0-150).

    Rescue antiemetic use. Management needs for severe PONV. Postoperative pain (VAS at rest and on movement) and opioid consumption. Device-related adverse events (skin irritation, burning, allergy). Drug-related adverse events (e.g., hyperglycemia, hypotension, headache, dizziness, QT prolongation).

    Intraoperative hemodynamics and postoperative complications (e.g., infection, shivering, urinary retention).

    3.5 Follow-up Schedule Postoperative day 1 (24 h): PONV assessment, time to first flatus and ambulation.

    Postoperative day 2 (48 h): PONV incidence/severity, rescue medication. At discharge: Satisfaction, hospital stay (via in-person or telephone follow-up).

  4. Sample Size Calculation Assumptions: PONV incidence 50% in control groups, 30% in TEAS groups; two-sided α = 0.05; power = 80%.

    Each main effect level requires \~93 patients. For a 2×2 factorial design with 1:1:1:1 allocation, this translates to 47 patients per group (total 188). Accounting for a 10% dropout rate, final sample size = 212 patients (53 per group).

  5. Data Management and Confidentiality Electronic Data Capture (EDC) system with unique coding (no direct identifiers).

    Access restricted to authorized research team members.

  6. Informed Consent Written informed consent will be obtained from each participant after full explanation of the study purpose, procedures, risks, and benefits. Participants are informed of their right to withdraw at any time.
  7. Adverse Event Management Dexamethasone-related AEs (transient hyperglycemia, blood pressure fluctuation, gastrointestinal discomfort, rare allergic reactions).

Amisulpride-related AEs (headache, dizziness, constipation/diarrhea, QT prolongation, allergic reactions).

TEA-related AEs (local skin discomfort, redness, itching, rare blisters or mild burns).

03

Conditions studied

  • Nausea and Vomiting, Postoperative
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years;
  • I-II;
  • Scheduled for elective gynecological laparoscopic surgery (e.g., ovarian cystectomy, myomectomy) under general anesthesia;
  • Willing to provide .

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac, hepatic, renal, or pulmonary disease;
  • Allergy or skin disease at TEAS application site;
  • Use of antiemetics within 24 hours before surgery; pregnancy or lactation;
  • Vulnerable populations (e.g., critically ill, psychiatric disorders, cognitive impairment, illiteracy);
  • Any condition deemed unsuitable by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    TEAS + Dexamethasone

    Participants in this arm receive both transcutaneous electrical acupoint stimulation (TEAS) and dexamethasone. TEAS: Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator. Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation. The highest well-tolerated intensity will then be maintained for treatment. Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.

    Drug: Dexamethasone (intravenous) · Device: Transcutaneous electrical acupoint stimulation (TEAS)

  • Experimental
    TEAS + Amisulpride

    Participants in this arm receive both transcutaneous electrical acupoint stimulation (TEAS) and amisulpride. TEAS: Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator. Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation. The highest well-tolerated intensity will then be maintained for treatment. Amisulpride: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.

    Drug: Amisulpride Injection · Device: Transcutaneous electrical acupoint stimulation (TEAS)

  • Experimental
    Sham stimulation + Dexamethasone

    Participants in this arm receive both sham transcutaneous electrical acupoint stimulation (TEAS) and dexamethasone. Sham stimulation: Electrodes are placed at the P6 acupoint (inner forearm, approximately 2 cun proximal to the wrist crease) for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. The device is attached but does not deliver any electrical output (no current). Participants are blinded to the stimulation status. Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.

    Drug: Dexamethasone (intravenous)

  • Experimental
    Sham stimulation + Amisulpride

    Participants in this arm receive both sham transcutaneous electrical acupoint stimulation (TEAS) and amisulpride. Sham stimulation: Electrodes are placed at the P6 acupoint (inner forearm, approximately 2 cun proximal to the wrist crease) for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. The device is attached but does not deliver any electrical output (no current). Participants are blinded to the stimulation status. Amisulpride: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.

    Drug: Amisulpride Injection

Interventions

  • DrugAmisulprideStudies of AmisulprideAmisulpride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Amisulpride:Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.

  • DrugDexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.

  • DeviceTranscutaneous electrical acupoint stimulation (TEAS)

    Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator. Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation. The highest well-tolerated intensity will then be maintained for treatment.

06

What researchers measure

Primary outcomes

  1. PONV incidence within 48 hours postoperatively

    Proportion of patients experiencing nausea, vomiting, or retching.

    Time frame: within 48 hours

  2. PONV severity

    Assessed using a 4-grade scale: Grade 0 = no nausea or vomiting Grade 1 = nausea only Grade 2 = vomiting or retching Grade 3 = refractory nausea and vomiting

    Time frame: within 48 hours

Secondary outcomes

  1. Nausea

    The number of nausea episodes recorded after surgery

    Time frame: 24 hours and 48 hours after surgery

  2. Vomiting

    The number of vomiting episodes recorded after surgery.

    Time frame: 24 hours and 48 hours after surgery

  3. Retching

    The number of retching episodes recorded after surgery.

    Time frame: 24 hours and 48 hours after surgery

  4. Time to first flatus

    The time from the end of surgery to the first passage of flatus after transfer from the post-anesthesia care unit (PACU) to the ward.

    Time frame: Up to 48 hours after surgery

  5. Time to first ambulation

    The time from the end of surgery to the patient's first out-of-bed activity.

    Time frame: Up to 48 hours after surgery

  6. Length of hospital stay

    Duration of postoperative hospitalization, measured in days.

    Time frame: Up to 7 days after surgery

  7. Bowel function recovery

    Assessed by the time of defecation.

    Time frame: Up to 48 hours postoperatively

  8. Quality of recovery (QoR-15)

    QoR-15 questionnaire score ranging from 0 to 150, covering 15 dimensions including physical comfort, emotional state, and psychological well-being.

    Time frame: Up to 24 hours postoperatively

  9. Rescue antiemetic use

    The type and number of rescue antiemetic medications required when a patient experiences PONV postoperatively.

    Time frame: Up to 48 hours postoperatively

  10. Number of Participants Requiring Management for Severe PONV

    Number of participants with severe postoperative nausea and vomiting, such as persistent vomiting or retching, requiring urgent additional amisulpride or other interventions.

    Time frame: Up to 48 hours postoperatively

  11. Postoperative pain (VAS at rest)

    Pain intensity measured at rest using a Visual Analogue Scale (0 = no pain, 10 = worst possible pain).

    Time frame: Assessed at 24, 48, and 72 hours after surgery

  12. Postoperative pain (VAS on movement)

    Pain intensity measured during movement (e.g., turning, coughing) using a Visual Analogue Scale (0 = no pain, 10 = worst possible pain).

    Time frame: Assessed at 24, 48, and 72 hours after surgery

  13. Postoperative opioid consumption

    Total amount of opioids consumed after surgery.

    Time frame: Assessed at 48 hours after surgery.

Other outcomes

  1. Device-related adverse events

    Adverse events associated with TEAS or sham stimulation, including local skin irritation, burning sensation, redness, itching, blistering, or mild burns at the electrode site.

    Time frame: Assessed after TEAS treatment before surgery, 24 hours after surgery, and 48 hours after surgery.

  2. Drug-related adverse events

    Adverse events related to dexamethasone or amisulpride, including but not limited to headache, dizziness, constipation, diarrhea, facial flushing, QT prolongation, allergic reactions (rash, dyspnea, hypotension), transient hyperglycemia, and blood pressure fluctuations.

    Time frame: Assessed at 24 and 48 hours after surgery.

  3. Proportion of Participants Receiving Intraoperative Vasoactive Drugs

    Proportion of participants who received any vasoactive medication during surgery.

    Time frame: Intraoperative period

  4. Postoperative complications

    Occurrence of complications after surgery, including infection, shivering, and urinary retention.

    Time frame: Up to 7 days after surgery

  5. Headache

    Number of patients with postoperative headache

    Time frame: 24 hours and 48 hours after surgery

  6. Dizziness

    Number of patients with postoperative dizziness

    Time frame: 24 hours and 48 hours after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No participant consent for data sharing Ethical approval does not permit it Chinese regulations restrict sharing of sensitive health data No data sharing agreement or infrastructure in place

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2026, 3 months later.

Of 181 non-industry interventional studies with no phase under Postoperative Nausea and Vomiting, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 3 months is below that.

Counting every sponsor, half of 181 studies reached it within 13 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Jun 8, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07631910
Responsible party
Gang Chen (Director of the Department of Anesthesiology, Sir Run Run Shaw Hospital) — Principal investigator
First posted
Jun 8, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Jun 8, 2026

Study contacts

Zhengjie Chen, M.D.
Contact
chenzhengjie@zju.edu.cn
86 13634226323
Gang Chen, M.D.
Contact
chengang120@zju.edu.cn
86 13757118681
Youjia Yu, M.D.
study chair · Sir Run Run Shaw Hospital
Gang Chen, M.D.
principal investigator · Sir Run Run Shaw Hospital
Zhengjie Chen, M.D.
study director · Sir Run Run Shaw Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amisulpride · Dexamethasone

Start the discussion